Alturos Therapeutics BV has advanced its lead candidate, ALT-0135, into IND-enabling studies. Alturos is targeting the earliest toxic triggers in Alzheimer’s disease, particularly protein oligomers that drive synaptic loss and neuronal death.
Saniona AB has presented preclinical data and its clinical development strategy for its lead clinical candidate, SAN-2668, which is a GABA-A receptor positive allosteric modulator under development for the treatment of severe pediatric epilepsies.
Cenna Biosciences Inc. has obtained IND clearance from the FDA for 8M2D, a first-in-class peptide for the treatment of Alzheimer’s disease. A phase Ia/Ib trial of 8M2D in healthy volunteers and patients with early Alzheimer’s disease is expected to begin dosing late this year.
Ignis Therapeutics (Suzhou) Co. Ltd. has synthesized new tetrahydroisoquinoline compounds acting as dopamine D1 receptor positive allosteric modulators (PAMs) potentially useful for the treatment of apathy, Parkinson’s disease, Huntington’s disease, dystonia, Alzheimer’s disease, neuropathic pain, psychosis and sleep disorder and among others.
Vedana Therapeutics has emerged from stealth with $46 million in series A financing. The company is developing next-generation, preventive therapies for migraine by leveraging pituitary adenylate cyclase-activating polypeptide (PACAP) biology, and highly selective combinatorial targeting of clinically validated pathways.
Acumen Pharmaceuticals Inc. has nominated ACU-301 and ACU-401 as development candidates in its Enhanced Brain Delivery (EBD) program as treatments for Alzheimer’s disease.
Shanghai Huilun Pharmaceutical Co. Ltd. has identified new angiotensin AT2 receptor antagonists potentially useful for the treatment of neuropathic pain.
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating neuronal proliferation, differentiation and synaptic maturation. Researchers from Shanghai Jiao Tong University School of Medicine generated Csnk2b haploinsufficient (Csnk2b+/-) mice mimicking the most relevant disease features to investigate the effects of reduced gene dosage.
JW Pharmaceutical Corp. has presented data on DDC-02 across animal models of several rare neurodevelopmental disorders, including Pitt-Hopkins syndrome, fragile X syndrome and Rett syndrome. Across these models, DDC-02 consistently restored deficits in cognitive and behavioral function.
RSS
